Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.64 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.60 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.60 |
| ▸ | ITGAL | P20701 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28067636 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL31477993 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL30557742 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL11873462 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL2182648 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL28067637 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL2182644 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL31619984 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL11873471 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 | |
| SCHEMBL11853752 | 0.93 | LTA4H (0.69) | ERAP1ERAP2LNPEPACEALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500252-B1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO BIO LTD (GB) | 2022-11-02 | — | — | EP | disclosed |
| US-20210094983-A1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO-BIO LTD. (GB) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094983-A1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | IAPP, NLN, APP | ERAP1 40/4885ERAP2 51/4885LNPEP 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.